Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

1998 • 19,638 citations

Glucose clamp technique: a method for quantifying insulin secretion and resistance.

1979 • 7,240 citations

Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies

2000 • 2,022 citations

GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN

1987 • 1,845 citations

Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men

1994 • 1,842 citations

Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM

1997 • 1,611 citations

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

1999 • 1,207 citations

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

1993 • 1,064 citations

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

1995 • 741 citations

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects

1995 • 705 citations

Abdominal Fat and Insulin Resistance in Normal and Overweight Women: Direct Measurements Reveal a Strong Relationship in Subjects at Both Low and High Risk of NIDDM

1996 • 630 citations

Effects of weight loss on regional fat distribution and insulin sensitivity in obesity.

1999 • 604 citations

β-cells in type II diabetes mellitus

1991 • 582 citations

Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

1984 • 481 citations

United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes Mellitus

1996 • 468 citations

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1996 • 460 citations

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

1999 • 343 citations

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1999 • 335 citations

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

1996 • 286 citations

Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial

1993 • 232 citations

Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes.

2000 • 226 citations

Physiological Importance of Deficiency in Early Prandial Insulin Secretion in Non-Insulin-Dependent Diabetes

1988 • 216 citations

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

1995 • 199 citations

Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans

1989 • 191 citations

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.

1997 • 174 citations

Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment

2001 • 172 citations

The Determinants of Glycemic Responses to Diet Restriction and Weight Loss in Obesity and NIDDM

1998 • 158 citations

Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.

2000 • 119 citations

Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7–36) Amide in Patients With NIDDM

1996 • 115 citations

Increased Resting Metabolic Rates in Obese Subjects with Non-insulin-dependent Diabetes Mellitus and the Effect of Sulfonylurea Therapy

1986 • 96 citations

Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus

1997 • 86 citations

Insulin Signal Transduction in Skeletal Muscle From Glucose-Intolerant Relatives With Type 2 Diabetes

2001 • 81 citations

Assessment of Hepatic Insulin Action in Obese Type 2 Diabetic Patients

2001 • 75 citations

Effect of Nutrient Ingestion on Glucagon-Like Peptide 1 (7-36 Amide) Secretion in Human Type 1 and Type 2 Diabetes

2000 • 59 citations